HLB Innovation Unveils Preclinical Results of Verismo's Solid Tumor CAR-T
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical solid tumor CAR-T data at a conference; early-stage, no revenue size given.
HLB innoVationHLB이노베이션
024850 · KOSDAQ · ₩024850 · HLB이노베이션
₩14,900▲ ₩200 (1.36%)End-of-day · Oct 28, 2026 · End-of-day prices.
HLB Innovation's Verismo Unveils Solid Tumor CAR-T Preclinical Data at SITC, Claims Lower T-Cell Exhaustion and Toxicity
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical CAR-T data at a conference; early-stage with no revenue impact.
Also known as: HLB innoVation / HLB이노베이션 / 024850 / KRX:024850
Source: KRX statistical information